Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Inflammopharmacology
Published in: Inflammopharmacology 3/2017

01-06-2017 | Review

Potential drug targets and treatment of schizophrenia

Authors: Anil Kumar, Monu Yadav, Milind Parle, Sameer Dhingra, Dinesh K. Dhull

Published in: Inflammopharmacology | Issue 3/2017

Login to get access

Abstract

Schizophrenia is one of the most prevalent chronic psychiatric disorders that affect 1% of the world’s population. Despite its societal burden, pathophysiology of schizophrenia remains poorly understood. Currently available drugs predominantly control positive symptoms, and often have no or poor control on negative and related cognitive symptoms, which strongly affect functional outcome in schizophrenia. The present article is an attempt to provide a critical review of recent hypothesis to understand pathophysiology of schizophrenia and to highlight exploitable molecular drug targets other than dopaminergic systems to treat and manage schizophrenia effectively.
Literature
Akyol O, Zoroglu SS, Armutcu F, Sahin S, Gurel A (2004) Nitric oxide as a physiopathological factor in neuropsychiatric disorders. In Vivo 18:377–390PubMed
Allan ER, Alpert M, Sison CE, Citrome L, Laury G, Berman I (1996) Adjunctive nadolol in the treatment of acutely aggressive schizophrenic patients. J Clin Psychiatry 57:455–459PubMedCrossRef
Altamura AC, Mauri MC, Mantero M, Brunetti M (1987) Clonazepam/haloperidol combination therapy in schizophrenia: a double blind study. Acta Psychiatr Scand 76:702–706PubMedCrossRef
Asevedo E, Gadelha A, Noto C, Mansur RB, Zugman A, Belangero SI, Berberian AA, Scarpato BS, Leclerc E, Teixeira AL, Gama CS, Bressan RA, Brietzke E (2013) Impact of peripheral levels of chemokines, BDNF and oxidative markers on cognition in individuals with schizophrenia. J Psychiatr Res 47:1376–1382PubMedCrossRef
Bardgett ME, Griffith MS, Foltz RF, Hopkins JA, Massie CM, O’Connell SM (2006) The effects of clozapine on delayed spatial alternation deficits in rats with hippocampal damage. Neurobiol Learn Memory 85(1):86–94CrossRef
Barnes NM, Sharp T (1999) A review of central 5-HT receptors and their function. Neuropharmacology 38:1083–1152PubMedCrossRef
Bartoli F, Dell’Osso B, Crocamo C, Fiorillo A, Ketter TA, Suppes T, Clerici M, Carrà G (2017) Benefits and harms of low and high second-generation antipsychotics doses for bipolar depression: a meta-analysis. J Psychiatr Res 88:38–46PubMedCrossRef
Berman I, Sapers BL, Chang HH, Losonczy MF, Schmildler J, Green AI (1995) Treatment of obsessive-compulsive symptoms in schizophrenic patients with clomipramine. J Clin Psychopharmacol 15(3):206–210PubMedCrossRef
Bernstein HG, Bogerts B, Keilhoff G (2005) The many faces of nitric oxide in schizophrenia. A review. Schizophr Res 78:69–86PubMedCrossRef
Binder EB, Kinkead B, Owens MJ, Nemeroff CB (2001) The role of neurotensin in the pathophysiology of schizophrenia and the mechanism of action of antipsychotic drugs. Biol Psychiatry 50:856–872PubMedCrossRef
Bodkin JA, Cohen BM, Salomon MS, Cannon SE, Zornberg GL, Cole JO (1996) Treatment of negative symptoms in schizophrenia and schizoaffective disorder by selegiline augmentation of antipsychotic medication. A pilot study examining the role of dopamine. J Nerv Ment Dis 184:295–301PubMedCrossRef
Bredt DS (1999) Endogenous nitric oxide synthesis: biological functions and pathophysiology. Free Radic Res. 31(6):577–596PubMedCrossRef
Brisch R, Bernstein HG, Krell D, Dobrowolny H, Bielau H, Steiner J, Gos T, Funke S, Stauch R, Knüppel S, Bogerts B (2009) Dopamine-glutamate abnormalities in the frontal cortex associated with the catechol-O-methyltransferase (COMT) in schizophrenia. Brain Res 1269:166–175PubMedCrossRef
Buchanan RW, Summerfelt A, Tek C, Gold J (2003) An open-labeled trial of adjunctive donepezil for cognitive impairments in patients with schizophrenia. Schizophr Res 59:29–33PubMedCrossRef
Caceda R, Kinkead B, Nemeroff CB (2006) Neurotensin: role in psychiatric and neurological diseases. Peptides 27:2385–2404PubMedCrossRef
Carlsson A (1988) The current status of the dopamine hypothesis of schizophrenia. Neuropsychopharmacol 1:179–186CrossRef
Carlsson ML, Carlsson A, Nilsson M (2004) Schizophrenia: from dopamine to glutamate and back. Curr Med Chem 11:267–277PubMedCrossRef
Carpenter WT Jr, Heinrichs DW, Wagman AM (1988) Deficit and nondeficit forms of schizophrenia: the concept. Am J Psychiatry 145:578–583PubMedCrossRef
Carpenter LL, McDougle CJ, Epperson CN, Price LH (1996) A risk-benefit assessment of drugs used in the management of obsessive-compulsive disorder. Drug Saf 15(2):116–134PubMedCrossRef
Caspi N, Modai I, Barak P, Waisbourd A, Zbarsky H, Hirschmann S, Ritsner M (2001) Pindolol augmentation in aggressive schizophrenic patients: a double-blind crossover randomized study. Int Clin Psychopharmacol 16:111–115PubMedCrossRef
Chopra K, Baveja A, Kuhad A (2015) MMPs: a novel drug target for schizophrenia. Expert Opin Ther Targets 19(1):77–85PubMedCrossRef
Ciobica A, Padurariu M, Dobrin I, Stefanescu C, Dobrin R (2011) Oxidative stress in schizophrenia—focusing on the main markers. Psychiatr Danub 23:237–245PubMed
Cioffi CL (2013) Modulation of NMDA receptor function as a treatment for schizophrenia. Bioorg Med Chem Lett 23:5034–5044PubMedCrossRef
Colquhoun LM, Patrick JW (1997) Pharmacology of neuronal nicotinic acetylcholine receptor subtypes. Adv Pharmacol 39:191–220PubMedCrossRef
Coskran TM, Morton DG, Menniti FS, Adamowicz WO, Kleiman RJ, Ryan AM, Strick CA, Schmidt CJ, Stephenson DT (2006) Immunohistochemical localization of phosphodiesterase 10A, PDE10A, in multiple mammalian species. J Histochem Cytochem 54:1205–1213PubMedCrossRef
Coyle J (1997) The nagging question of the function of N acetylaspartylglutamate. Neurobiol Dis 4:231–238PubMedCrossRef
Crook JM, Tomaskovic-Crook E, Copolov DL, Dean B (2000) Decreased muscarinic receptor binding in subjects with schizophrenia: a study of the human hippocampal formation. Biol Psychiatry 48:381–388PubMedCrossRef
Davis J, Moylan S, Harvey BH, Maes M, Berk M (2014) Neuroprogression in schizophrenia: pathways underpinning clinical staging and therapeutic corollaries. Aust NZ J Psychiatry 48:512–529CrossRef
Dawson LA, Smith PW (2010) Therapeutic utility of NK3 receptor antagonists for the treatment of schizophrenia. Curr Pharm Des 16:344–357PubMedCrossRef
De Marchi N, De Petrocellis L, Orlando P, Daniele F, Fezza F, Di Marzo V (2003) Endocannabinoid signalling in the blood of patients with schizophrenia. Lipids Health Dis 2:5PubMedPubMedCentralCrossRef
Dean B, Sundram S, Bradbury R, Scarr E, Copolov D (2001) Studies on [3H]CP-55940 binding in the human central nervous system: regional specific changes in density of cannabinoid 1 receptors associated with schizophrenia and cannabis use. Neuroscience 103:9–15PubMedCrossRef
Di Giovanni G, Di Matteo V, Di Mascio M, Esposito E (2000) Preferential modulation of mesolimbic vs. nigrostriatal dopaminergic function by serotonin(2C/2B) receptor agonists: a combined in vivo electrophysiological and microdialysis study. Synapse 35(1):53–61PubMedCrossRef
Dietrich-Muszalska A (2015) Oxidative stress in schizophrenia. Studies on psychiatric disorders. Springer, New York, pp 43–72
Dose M, Hellweg R, Yassouridis A, Theison M, Emrich HM (1998) Combined treatment of schizophrenic psychoses with haloperidol and valproate. Pharmacopsychiatry 31:122–125PubMedCrossRef
Ebstein RP, Biederman J, Rimon R, Zohar J, Belmaker RJ (1976) Cyclic GMP in the CSF of patients with schizophrenia before and after neuroleptic treatment. Psychopharmacology 51(1):71–74PubMedCrossRef
Emrich HM, Leweke FM, Schneider U (1997) Towards a cannabinoid hypothesis of schizophrenia: cognitive impairments due to dysregulation of the endogenous cannabinoid system. Pharmacol Biochem Behav 56:803–807PubMedCrossRef
Evins AE, Fitzgerald SM, Wine L, Rosselli R, Goff DC (2000) Placebo-controlled trial of glycine added to clozapine in schizophrenia. Am J Psychiatry 157:826–828PubMedCrossRef
Feifel D, Reza TL, Wustrow DJ, Davis MD (1999) Novel antipsychotic-like effects on prepulse inhibition of startle produced by a neurotensin agonist. J Pharmacol Exp Ther 288:710–713PubMed
Fell MJ, McKinzie DL, Monn JA, Svensson KA (2012) Group II metabotropic glutamate receptor agonists and positive allosteric modulators as novel treatments for schizophrenia. Neuropharmacology 62:1473–1483PubMedCrossRef
Fenton WS, Dickerson F, Boronow J, Hibbeln JR, Knable M (2001) A placebo-controlled trial of omega-3 fatty acid (ethyl eicosapentaenoic acid) supplementation for residual symptoms and cognitive impairment in schizophrenia. Am J Psychiatry 158:2071–2074PubMedCrossRef
Ferraro L, Tomasini MC, Fuxe K, Agnati LF, Mazza R, Tanganelli S, Antonelli T (2007) Mesolimbic dopamine and cortico-accumbens glutamate afferents as major targets for the regulation of the ventral striato-pallidal GABA pathways by neurotensin peptides. Brain Res Rev 55:144–154PubMedCrossRef
Finberg JP, Youdim MB (2002) Pharmacological properties of the anti-Parkinson drug rasagiline; modification of endogenous brain amines, reserpine reversal, serotonergic and dopaminergic behaviours. Neuropharmacology 43:1110–1118PubMedCrossRef
Freeman MP, Hibbeln JR, Wisner KL, Davis JM, Mischoulon D, Peet M, Keck PE Jr, Marangell LB, Richardson AJ, Lake J, Stoll AL (2006) Omega-3 fatty acids: evidence basis for treatment and future research in psychiatry. J Clin Psychiatry 67:1954–1967PubMedCrossRef
Friedman JI, Adler DN, Howanitz E, Harvey PD, Brenner G, Temporini H, White L, Parrella M, Davis KL (2002) A double blind placebo controlled trial of donepezil adjunctive treatment to risperidone for the cognitive impairment of schizophrenia. Biol Psychiatry 51:349–357PubMedCrossRef
Ganzinelli S, Borda E, Sterin-Borda L (2010) Autoantibodies from schizophrenia patients induce cerebral cox-1/iNOS mRNA expression with NO/PGE2/MMP-3 production. Int J Neuropsychopharmacol 13:293–303PubMedCrossRef
Gattaz WF, Carmer H, Beckmann H (1983) Low CSF concentrations of cyclic GMP in schizophrenia. Br J Psychiatry 142:288–291PubMedCrossRef
Goff DC, Coyle JT (2001) The emerging role of glutamate in the pathophysiology and treatment of schizophrenia. Am J Psychiatry 158:1367–1377PubMedCrossRef
Goff DC, Tsai G, Levitt J, Amico E, Manoach D, Schoenfeld DA, Hayden DL, McCarley R, Coyle JT (1999) A placebo-controlled trial of d-cycloserine added to conventional neuroleptics in patients with schizophrenia. Arch Gen Psychiatry 56:21–27PubMedCrossRef
Gray JA, Roth BL (2007) The pipeline and future of drug development in schizophrenia. Mol Psychiatry 12(10):904–922PubMedCrossRef
Griebel G, Beeske S (2011) Is there still a future for neurokinin 3 receptor antagonists as potential drugs for the treatment of psychiatric diseases? Pharmacol Ther 133:116–123PubMedCrossRef
Gupta VK, Sharma SK (2006) Plants as natural antioxidants. Nat Prod Radiance. 5(4):326–334
Gupta S, Droney T, Kyser A, Keller P (1999) Selegiline augmentation of antipsychotics for the treatment of negative symptoms in schizophrenia. Compr Psychiatry 40:148–150PubMedCrossRef
Gutteridge JMC (1995) Free radicals in disease processes: a compilation of cause and consequence. Free Radic Res Commun 19:141CrossRef
Harvey PD, Keefe RSE (2001) Studies of cognitive change in patients with schizophrenia following novel antipsychotic treatment. Am J Psychiatry 158:176–184PubMedCrossRef
Hayashi T, Su TP (2004) Sigma-1 receptor ligands: potential in the treatment of neuropsychiatric disorders. CNS Drugs 18(5):269–284PubMedCrossRef
He J, Yang Y, Xu H, Zhang X, Li XM (2005) Olanzapine attenuates the okadaic acid-induced spatial memory impairment and hippocampal cell death in rats. Neuropsychopharmacology 30(8):1511–1520PubMedCrossRef
Hemish J, Nakaya N, Mittal V, Enikolopov G (2003) Nitric oxide activates diverse signaling pathways to regulate gene expression. J Biol Chem 278:42321–42329PubMedCrossRef
Heresco-Levy U, Javitt DC, Ermilov M, Mordel C, Horowitz A, Kelly D (1996) Double-blind, placebo-controlled, crossover trial of glycine adjuvant therapy for treatment-resistant schizophrenia. Br J Psychiatry 169:610–617PubMedCrossRef
Hesslinger B, Normann C, Langosch JM, Klose P, Berger M, Walden J (1999) Effects of carbamazepine and valproate on haloperidol plasma levels and on psychopathologic outcome in schizophrenic patients. J Clin Psychopharmacol 19:310–315PubMedCrossRef
Hobbs AJ, Ignarro LJ (1996) Nitric oxide-cyclic GMP signal transduction system. Methods Enzymol 269:134–148PubMedCrossRef
Hoffer A (1960) Adrenaline metabolites and schizophrenia. Dis Nerv Syst 21:79PubMed
Hoffer A, Prousky J (2008) Successful treatment of schizophrenia requires optimal daily doses of vitamin B3. Altern Med Rev 13(4):287–291PubMed
Hosak L, Libiger J (2002) Antiepileptic drugs in schizophrenia: a review. European psychiatry 17(7):371–378PubMedCrossRef
Hunter R (2014) Developing tomorrow’s antipsychotics: the need for a more personalised approach. Adv Psychiatr Treat 20(1):3–12CrossRef
Idänpään-Heikkilä J, Alhava E, Olkinuora M, Palva IP (1977) Agranulocytosis during treatment with chlozapine. Eur J Clin Pharmacol 11(3):193–198PubMedCrossRef
Insel TR (2010) Rethinking schizophrenia. Nature 468:187e93
Javitt DC, Zukin SR (1991) Recent advances in the phenciclidine model of schizophrenia. Am J Psychiatry 148:1301–1308PubMedCrossRef
Javitt DC, Silipo G, Cienfuegos A, Shelley AM, Bark N, Park M, Lindenmayer JP, Suckow R, Zukin SR (2001) Adjunctive high-dose glycine in the treatment of schizophrenia. Int J Neuropsychopharmacol 4:385–391PubMedCrossRef
Jones CK, Byun N, Bubser M (2012) Muscarinic and nicotinic acetylcholine receptor agonists and allosteric modulators for the treatment of schizophrenia. Neuropsychopharmacology 37(1):16–42PubMedCrossRef
Kapur S, Seeman P (2000) Antipsychotic agents differ in how fast they come off the dopamine D2 receptors: implications for atypical antipsychotic action. J Psychiatry Neurosci 25:161–166PubMedPubMedCentral
Kasckow J, Nemeroff CB (1991) The neurobiology of neurotensin: focus on neurotensin–dopamine interactions. Regul Pept 36:153–164PubMedCrossRef
Kay SR, Fiszbein A, Opler LA (1987) The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull 13(2):261–276PubMedCrossRef
Keefe RS, Bilder RM, Davis SM, Harvey PD, Palmer BW, Gold JM, Meltzer HY, Green MF, Capuano G, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO, Davis CE, Hsiao JK, Lieberman JA, CATIE Investigators, Neurocognitive Working Group (2007) Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE Trial. Arch Gen Psychiatry 64(6):633–647PubMedCrossRef
King MV, Sleight AJ, Woolley ML, Topham IA, Marsden CA, Fone KC (2004) 5-HT6 receptor antagonists reverse delay-dependent deficits in novel object discrimination by enhancing consolidation—an effect sensitive to NMDA receptor antagonism. Neuropharmacology 47(2):195–204PubMedCrossRef
Kirli S, Caliskan M (1998) A comparative study of sertraline versus imipramine in postpsychotic depressive disorder of schizophrenia. Schizophr Res 33:103–111PubMedCrossRef
Klein DF, Davis JM (1969) Diagnosis and drug treatment of psychiatric disorders. Krieger, Huntington
Kontis D, Theochari E, Fryssira H, Kleisas S, Sofocleous C, Andreopoulou A, Kalogerakou S, Gazi A, Boniatsi L, Chaidemenos A, Tsaltas E (2013) COMT and polymorphisms interaction on cognition in schizophrenia: an exploratory study. Neurosci Lett 537:17–22PubMedCrossRef
Kroeze WK, Hufeisen SJ, Popadak BA, Renock SM, Steinberg S, Ernsberger P, Jayathilake K, Meltzer HY, Roth BL (2003) H1-histamine receptor affinity predicts short-term weight gain for typical and atypical antipsychotic drugs. Neuropsychopharmacology 28:519–526PubMedCrossRef
Kroken RA, Loberg EM, Dronen T, Gruner R, Hugdahl K, Kompus K, Skrede S, Johnsen E (2014) A critical review of pro-cognitive drug targets in psychosis: convergence on myelination and inflammation. Front Psychiatry 5:11PubMedPubMedCentralCrossRef
Kuperberg G, Kerwin R, Murray R (2002) Developments in the pharmacological treatment of schizophrenia. Expert Opin Investig Drugs 11(10):1335–1341PubMedCrossRef
Lambert P, Perrin J, Revol L et al (1959) Essai de classification des neuroleptiques d’après leurs activités psychopharmacologiques et cliniques. In: Bradley PB, Deniker P, Radouco-Thomas C (eds) Neuropsychopharmacology. Elsevier, Amsterdam, pp 619–624
Large CH, Webster EL, Goff DC (2005) The potential role of lamotrigine in schizophrenia. Psychopharmacology 181(3):415–436PubMedCrossRef
Laruelle M, Kegeles LS, Abi-Dargham A (2003) Glutamate, dopamine, and schizophrenia from pathophysiology to treatment. Ann NY Acad Sci 1003:138–158PubMedCrossRef
Levey AI, Kitt CA, Simonds WF, Price DL, Brann MR (1991) Identification and localization of muscarinic acetylcholine receptor proteins in brain with subtype-specific antibodies. J Neurosci 11:3218–3226PubMed
Liljequist R, Haapalinna A, Ahlander M, Li YH, Mannisto PT (1997) Catechol O-methyltransferase inhibitor tolcapone has minor influence on performance in experimental memory models in rats. Behav Brain Res 82:195–202PubMedCrossRef
Lin A, Kenis G, Bignotti S, Tura GJ, De Jong R, Bosmans E, Pioli R, Altamura C, Scharpe S, Maes M (1998) The inflammatory response system in treatment-resistant schizophrenia: increased serum interleukin-6. Schizophr Res 32:9–15PubMedCrossRef
Litman RE, Su TP, Potter WZ, Hong WW, Pickar D (1996) Idazoxan and response to typical neuroleptics in treatment-resistant schizophrenia. Comparison with the atypical neuroleptic, clozapine. Br J Psychiatry 168:571–579PubMedCrossRef
Madras BK (2013) History of the discovery of the antipsychotic dopamine D2 receptor: a basis for the dopamine hypothesis of schizophrenia. J Hist Neurosci 22:62–78PubMedCrossRef
Manatt M, Chandra SB (2011) The effects of mitochondrial dysfunction in schizophrenia. J Med Genet Genomics 3(5):84–94
Marazziti D, Baroni S, Picchetti M, Landi P, Silvestri S, Vatteroni E, Catena Dell’Osso M (2011) Mitochondrial alterations and neuropsychiatric disorders. Curr Med Chem 18:4715–4721PubMedCrossRef
Martin LF, Kem WR, Freedman R (2004) Alpha-7 nicotinic receptor agonists: potential new candidates for the treatment of schizophrenia. Psychopharmacology 174:54–64PubMedCrossRef
Maurer I, Zierz S, Möller H (2001) Evidence for a mitochondrial oxidative phosphorylation defect in brains from patients with schizophrenia. Schizophren Res 48:125–136CrossRef
Mayer B, Hemmens B (1997) Biosynthesis and action of nitric oxide in mammalian cells. Trends Biochem Sci 22:477–481PubMedCrossRef
Meiri KF, Saffell JL, Walsh FS, Doherty P (1998) Neurite outgrowth stimulated by neural cell adhesion molecules requires growth-associated protein-43 (GAP-43) function and is associated with GAP-43 phosphorylation in growth cones. J Neurosci 18:10429–10437PubMed
Meltzer HY (1989) Clinical studies on the mechanism of action of clozapine—the dopamine-serotonin hypothesis of schizophrenia. Psychopharmacology 99:S18–S27PubMedCrossRef
Meltzer D (1999) Perspective and the measurement of costs and benefits for cost effectiveness analysis in schizophrenia. J Clin Psychiatry 60(Suppl 3):32–35 (discussion 36–7) PubMed
Millan MJ, Schreiber R, Dekeyne A, Rivet JM, Bervoets K, Mavridis M, Sebban C, Maurel-Remy S, Newman-Tancredi A, Spedding M, Muller O, Lavielle G, Brocco M (1998) S 16924 ((R)-2-[1-[2-(2,3-dihydro-benzo[1,4]dioxin-5-yloxy)-ethyl]-pyrrolidin-3yl]-1-(4-fluoro-phenyl)-ethanone), a novel, potential antipsychotic with marked serotonin (5-HT)1A agonist properties: II. Functional profile in comparison to clozapine and haloperidol. J Pharmacol Exp Ther 286(3):1356–1373PubMed
Monji A, Kato T, Kanba S (2009) Cytokines and schizophrenia: microglia hypothesis of schizophrenia. Psychiatry Clin Neurosci 63(3):257–265PubMedCrossRef
Morris HM, Hashimoto T, Lewis DA (2008) Alterations in somatostatin mRNA expression in the dorsolateral prefrontal cortex of subjects with schizophrenia or schizoaffective disorder. Cereb Cortex 18:1575–1587PubMedPubMedCentralCrossRef
Muller N, Schwarz MJ (2008) COX-2 inhibition in schizophrenia and major depression. Current pharmaceutical design 14(14):1452–1465PubMedCrossRef
Negre-Aminou P, Pfenninger KH (1993) Arachidonic acid turnover and phospholipase A2 activity in neuronal growth cones. J Neurochem 60:1126–1136PubMedCrossRef
Ng F, Berk M, Dean O, Bush AI (2008) Oxidative stress in psychiatric disorders: evidence base and therapeutic implications. Int J Neuropsychopharmacol 11:851–876PubMedCrossRef
Nissinen L, Kahari VM (2014) Matrix metalloproteinases in inflammation. Biochim Biophys Acta 1840:2571–2580PubMedCrossRef
Oliveira JP, Zuardi AW, Hallak JE (2008) Role of nitric oxide in patients with schizophrenia—a systematic review of the literature. Curr Psychiatry Rev 4:219–227CrossRef
Osmond H, Smythies J (1952) Schizophrenia: a new approach. J Ment Sci 98(411):309–315PubMed
Parle M, Kadian R (2013a) Behavioral models of psychosis. Int Res J Pharm 7:26–30CrossRef
Parle M, Kadian R (2013b) Non behavioral models of psychosis. Int Res J Pharm 4(8):89–95CrossRef
Parle M, Sharma K (2013) Biomarker and causative factor of schizophrenia. Int Res J Pharm 4:78–85CrossRef
Peet M, Brind J, Ramchand CN, Shah S, Vankar GK (2001) Two double-blind placebo-controlled pilot studies of eicosapentaenoic acid in the treatment of schizophrenia. Schizophr Res 49:243–251PubMedCrossRef
Perenyi A, Goswami U, Frecska E, Arato M, Bela A (1992) l-Deprenyl in treating negative symptoms of schizophrenia. Psychiatry Res 42:189–191PubMedCrossRef
Pieczenik SR, Neustadt J (2007) Mitochondrial dysfunction and molecular pathways of disease. Exp Mol Pathol 83(1):84–92PubMedCrossRef
Piletz JE, Chikkala DN, Ernsberger P (1995) Comparison of the properties of agmatine and endogenous clonidine-displacing substance at imidazoline and alpha 2-adrenergic receptors. J Pharmacol Exp Ther 272:581–587PubMed
Piomelli D, Pilon C, Giros B, Sokoloff P, Martres MP, Schwartz JC (1991) Dopamine activation of the arachidonic acid cascade as a basis for D1/D2 receptor synergism. Nature 353:164–167PubMedCrossRef
Poulin B, Butcher A, McWilliams P, Bourgognon JM, Pawlak R, Kong KC, Bottrill A, Mistry S, Wess J, Rosethorne EM, Charlton SJ, Tobin AB (2010) The M3-muscarinic receptor regulates learning and memory in a receptor phosphorylation/arrestin-dependent manner. Proc Natl Acad Sci USA 107:9440–9445PubMedPubMedCentralCrossRef
Prabakaran S, Swatton JE, Ryan MM, Huffaker SJ, Huang JTJ, Griffin JL, Wayland M, Freeman T, Dudbridge F, Lilley KS, Karp NA, Hester S, Tkachev D, Mimmack ML, Yolken RH, Webster MJ, Torrey EF, Bahn S (2004) Mitochondrial dysfunction in schizophrenia: evidence for compromised brain metabolism and oxidative stress. Mol Psychiatry 9(684–97):643CrossRef
Puzzo D, Sapienza S, Arancio O, Palmeri A (2008) Role of phosphodiesterase 5 in synaptic plasticity and memory. Neuropsychiatr Dis Treat. 4(2):371–387PubMedPubMedCentralCrossRef
Raiteri M, Leardi R, Marchi M (1984) Heterogeneity of presynaptic muscarinic receptors regulating neurotransmitter release in the rat brain. J Pharmacol Exp Ther 228:209–214PubMed
Raiteri M, Marchi M, Paudice P, Pittaluga A (1990) Muscarinic receptors mediating inhibition of g-aminobutyric acid release in rat corpus striatum and their pharmacological characterization. J Pharmacol Exp Ther 254:496–501PubMed
Rajasekaran A, Venkatasubramanian G, Berk M, Debnath M (2015) Mitochondrial dysfunction in schizophrenia: pathways, mechanisms and implications. Neurosci Biobehav Rev 48:10–21PubMedCrossRef
Rao NP, Remington G (2013) Investigational drugs for schizophrenia targeting the dopamine receptor: phase II trials. Expert Opin Investig Drugs 22(7):881–894PubMedCrossRef
Reznik I, Sirota P (2000) An open study of fluvoxamine augmentation of neuroleptics in schizophrenia with obsessive and compulsive symptoms. Clin Neuropharmacol 23(3):157–160PubMedCrossRef
Richardson AJ (2006) Omega-3 fatty acids in ADHD and related neurodevelopmental disorders. Int Rev Psychiatry 18:155–172PubMedCrossRef
Riecher-Rossler A, Hafner H (2000) Gender aspects in schizophrenia: bridging the border between social and biological psychiatry. Acta Psychiatr Scand Suppl 102:58–62CrossRef
Risch SC, McGurk S, Horner MD, Nahas Z, Owens SD, Molloy M, Gilliard C, Christie S, Markowitz JS, DeVane CL, Mintzer J, George MS (2001) A double-blind placebo-controlled case study of the use of donepezil to improve cognition in a schizoaffective disorder patient: functional MRI correlates. Neurocase 7:105–110PubMedCrossRef
Rogers DC, Hagan JJ (2001) 5-HT6 receptor antagonists enhance retention of a water maze task in the rat. Psychopharmacology 158(2):114–119PubMedCrossRef
Rosenberg GA (2009) Matrix metalloproteinases and their multiple roles in neurodegenerative diseases. Lancet Neurol 8:205–216PubMedCrossRef
Roth BL, Hanizavareh SM, Blum AE (2004) Serotonin receptors represent highly favourable molecular targets for cognitive enhancement in schizophrenia and other disorders. Psychopharmacology 174:17–24PubMedCrossRef
Rouse ST, Edmunds SM, Yi H, Gilmor ML, Levey AI (2000) Localization of M(2) muscarinic acetylcholine receptor protein in cholinergic and non-cholinergic terminals in rat hippocampus. Neurosci Lett 284:182–186PubMedCrossRef
Rubeša G, Gudelj L, Kubinska N (2011) Etiology of schizophrenia and therapeutic options. Psychiatr Danub. 23(3):308–315PubMed
Rukmini MS, D’Souza B, D’Souza V (2004) Superoxide dismutase and catalase activities and their correlation with malondialdehyde in schizophrenic patients. Indian J Clin Biochem 19(2):114–118PubMedPubMedCentralCrossRef
Samochocki M, Höffle A, Fehrenbacher A, Jostock R, Ludwig J, Christner C, Radina M, Zerlin M, Ullmer C, Pereira EF, Lübbert H, Albuquerque EX, Maelicke A (2003) Galantamine is an allosterically potentiating ligand of neuronal nicotinic but not of muscarinic acetylcholine receptors. J Pharmacol Exp Ther 305(3):1024–1036PubMedCrossRef
Sarter M, Bruno JP (1997) Cognitive functions of cortical acetylcholine: toward a unifying hypothesis. Brain Res Brain Res Rev 23:28–46PubMedCrossRef
Saudou F, Hen R (1994) 5-Hydroxytryptamine receptor subtypes in vertebrates and invertebrates. Neurochem Int 25(6):503–532PubMedCrossRef
Schmidt CJ, Chapin DS, Cianfrogna J, Corman ML, Hajos M, Harms JF, Hoffman WE, Lebel LA, McCarthy SA, Nelson FR, Proulx-LaFrance C, Majchrzak MJ, Ramirez AD, Schmidt K, Seymour PA, Siuciak JA, Tingley FD 3rd, Williams RD, Verhoest PR, Menniti FS (2008) Preclinical characterization of selective phosphodiesterase 10A inhibitors: a new therapeutic approach to the treatment of schizophrenia. J Pharmacol Exp Ther 325(2):681–690PubMedCrossRef
Seeger TF, Bartlett B, Coskran TM, Culp JS, James LC, Krull DL, Lanfear J, Ryan AM, Schmidt CJ, Strick CA, Varghese AH, Williams RD, Wylie PG, Menniti FS (2003) Immunohistochemical localization of PDE10A in the rat brain. Brain Res 985:113–126PubMedCrossRef
Seeman P, Lee T (1975) Antipsychotic drugs: direct correlation between clinical potency and presynaptic action on dopamine neutrons. Science 188:1217–1219PubMedCrossRef
Selvaraj S, Arnone D, Cappai A, Howes O (2014) Alterations in the serotonin system in schizophrenia: a systematic review and meta-analysis of postmortem and molecular imaging studies. Neurosci Biobehav Rev 45:233–245PubMedCrossRef
Shekhawat LS, Jiloha RC (2009) Recent advances in the treatment of schizophrenia. Delhi Psych J 12(2):176–187
Siris SG, Bermanzohn PC, Mason SE, Shuwall MA (1994) Maintenance imipramine therapy for secondary depression in schizophrenia: a controlled trial. Arch Gen Psychiatry 51:109–115PubMedCrossRef
Siuciak JA, Chapin DS, Harms JF, Lebel LA, McCarthy SA, Chambers L, Shrikhande A, Wong S, Menniti FS, Schmidt CJ (2006) Inhibition of the striatum- enriched phosphodiesterase PDE10A: a novel approach to the treatment of psychosis. Neuropharmacology 51:386–396PubMedCrossRef
Skosnika PD, Yao JK (2003) From membrane phospholipid defects to altered neurotransmission: is arachidonic acid a nexus in the pathophysiology of schizophrenia? Prostaglandins Leukot Essent Fatty Acids 69:367–384CrossRef
Snyder SH, Banerjee SP, Yamamura HI, Greenberg D (1974) Drugs, neurotransmitters, and schizophrenia. Science 184:1243–1253PubMedCrossRef
Sorenson EM, Shiroyama T, Kitai ST (1998) Postsynaptic nicotinic receptors on dopaminergic neurons in the substantia nigra pars compacta of the rat. Neuroscience 87:659–673PubMedCrossRef
Spear N, Gadient RA, Wilkins DE, Do M, Smith JS, Zeller KL, Schroeder P, Zhang M, Arora J, Chhajlani V (2011) Preclinical profile of a novel metabotropic glutamate receptor 5 positive allosteric modulator. Eur J Pharmacol 659:146–154PubMedCrossRef
Spooren W, Riemer C, Meltzer H (2005) NK3 receptor antagonists: the next generation of antipsychotics? Nat Rev Drug Discov 4:967–975PubMedCrossRef
Steullet P, Cabungcal JH, Monin A, Dwir D, O’Donnell P, Cuenod M, Do KQ (2016) Redox dysregulation, neuroinflammation, and NMDA receptor hypofunction: a “central hub” in schizophrenia pathophysiology? Schizophr Res 176(1):41–51PubMedCrossRef
St-Gelais F, Menard C, Congar P, Trudeau LE, Massicotte G (2004) Postsynaptic injection of calcium-independent phospholipase A2 inhibitors selectively increases AMPA receptor-mediated synaptic transmission. Hippocampus 14:319–325PubMedCrossRef
Tsai G, Coyle JT (2002) Glutamatergic mechanisms in schizophrenia. Annu Rev Pharmacol Toxicol 42:165–179PubMedCrossRef
Tzavara ET, Bymaster FP, Felder CC, Wade M, Gomeza J, Wess J, McKinzie DL, Nomikos GG (2003) Dysregulated hippocampal acetylcholine neurotransmission and impaired cognition in M2, M4 and M2/M4 muscarinic receptor knockout mice. Mol Psychiatry 8:673–679PubMedCrossRef
Tzavara ET, Bymaster FP, Davis RJ, Wade MR, Perry KW, Wess J, McKinzie DL, Felder C, Nomikos GG (2004) M4 muscarinic receptors regulate the dynamics of cholinergic and dopaminergic neurotransmission: relevance to the pathophysiology and treatment of related CNS pathologies. FASEB J 18:1410–1412PubMed
Ungvari GS, Chiu HF, Chow LY, Lau BS, Tang WK (1999) Lorazepam for chronic catatonia: a randomized, double blind, placebo-controlled cross-over study. Psychopharmacology 142:393–398PubMedCrossRef
Uzbay IT, Kayir H, Göktalay G, Yildirim M (2008) Agmatine induces schizophrenia like-symptom in Wistar rats. Eur Neuropsychopharmacol 18(Suppl. 4):S399CrossRef
Vilaro MT, Palacios JM, Mengod G (1990) Localization of m5 muscarinic receptor mRNA in rat brain examined by in situ hybridization histochemistry. Neurosci Lett 114:154–159PubMedCrossRef
Vizi ES, Kobayashi O, Töröcsik A, Kinjo M, Nagashima H, Manabe N, Goldiner PL, Potter PE, Foldes FF (1989) Heterogeneity of presynaptic muscarinic receptors involved in modulation of transmitter release. Neuroscience 31:259–267PubMedCrossRef
Vyas NS, Patel NH, Puri BK (2011) Neurobiology and phenotypic expression in early onset schizophrenia. Early Interv Psychiatry 5:3–14PubMedCrossRef
Wamsley JK, Zarbin MA, Kuhar MJ (1984) Distribution of muscarinic cholinergic high and low affinity agonist binding sites: a light microscopic autoradiographic study. Brain Res Bull 12:233–243PubMedCrossRef
Wei J, Hemmings GP (1999) The CCK-A receptor gene possibly associated with auditory hallucinations in schizophrenia. Eur Psychiatry 14:67–70PubMedCrossRef
Weiner DM, Levey AI, Brann MR (1990) Expression of muscarinic acetylcholine and dopamine receptor mRNAs in rat basal ganglia. Proc Natl Acad Sci USA 87:7050–7054PubMedPubMedCentralCrossRef
Wils RS, Gotfredsen DR, Hjorthøj C, Austin SF, Albert N, Secher RG, Thorup AA, Mors O, Nordentoft M (2016) Antipsychotic medication and remission of psychotic symptoms 10 years after a first-episode psychosis. Schizophr Res (in press)
Wolkowitz OM, Pickar D (1991) Benzodiazepines in the treatment of schizophrenia: a review and reappraisal. Am J Psychiatry 148:714–726PubMedCrossRef
Xie Z, Adamowicz WO, Eldred WD, Jakowski AB, Kleiman RJ, Morton DG, Stephenson DT, Strick CA, Williams RD, Menniti FS (2006) Cellular and subcellular localization of PDE10A, a striatal-specific phosphodiesterase. Neuroscience 139:597–607PubMedPubMedCentralCrossRef
Yadav M, Parle M, Kadian M, Sharma K (2015) A review on psychosis and anti-psychotic plants. Asian J Pharm Clin Res 8(4):24–28
Yoshida K, Higuchi H, Hishikawa Y (1998) Marked improvement of tardive dystonia after replacing haloperidol with risperidone in a schizophrenic patient. Clin Neuropharmacol 21(1):68–69PubMed
Zang Z, Creese I (1997) Differential regulation of expression of rat hippocampal muscarinic receptor subtypes following fimbria–fornix lesion. Biochem Pharmacol 53:1379–1382PubMedCrossRef
Zhang W, Basile AS, Gomeza J, Volpicelli LA, Levey AI, Wess J (2002) Characterization of central inhibitory muscarinic autoreceptors by the use of muscarinic acetylcholine receptor knockout mice. J Neurosci 22:1709–1717PubMed
Zhang XY, Zhou DF, Cao LY, Zhang PY, Wu GY (2003) Elevated blood superoxide dismutase in neuroleptic-free schizophrenia: association with positive symptoms. J Psychiatr Res 117:85–88CrossRef
Ziimmer R, Teelken AW, Cramer H, Ackenheil M, Zandler KJ, Fischer H (1980) Short- and long-term effects on GABA and dopamine neurons during treatment with sulpiride. Adv Biochem Psychopharmacol 24:537–539
Metadata
Title
Potential drug targets and treatment of schizophrenia
Authors
Anil Kumar
Monu Yadav
Milind Parle
Sameer Dhingra
Dinesh K. Dhull
Publication date
01-06-2017
Publisher
Springer International Publishing
Published in
Inflammopharmacology / Issue 3/2017
Print ISSN: 0925-4692
Electronic ISSN: 1568-5608
DOI
https://doi.org/10.1007/s10787-017-0340-5

Other articles of this Issue 3/2017

Inflammopharmacology 3/2017 Go to the issue

Original Article

Curcumin inhibits lipopolysaccharide (LPS)-induced endotoxemia and airway inflammation through modulation of sequential release of inflammatory mediators (TNF-α and TGF-β1) in murine model

Review

Mammalian target of rapamycin (mTOR) as a potential therapeutic target in various diseases

Original Article

Sitagliptin and liraglutide reversed nigrostriatal degeneration of rodent brain in rotenone-induced Parkinson’s disease

Original Article

Curcumin protects dopaminergic neurons against inflammation-mediated damage and improves motor dysfunction induced by single intranigral lipopolysaccharide injection

Review

Obesity, cardiovascular disease, and role of vitamin C on inflammation: a review of facts and underlying mechanisms

Original Article

Evaluation of the protective effect of pentoxifylline on carrageenan-induced chronic non-bacterial prostatitis in rats